MedTrace Logo

Drug Repurposing - Statins as Microbiota Modulating Agents in Ulcerative Colitis

NCT04883840 · Status: TERMINATED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 177

Last updated 2025-11-25

No results posted yet for this study

Summary

* Evaluation of the microbiota modulation away from inflammation associated microbiota profile Bacteroides2 (Bact2)
* Evaluation of the effect of microbiota modulation on disease activity in ulcerative colitis and Crohn's disease patients.

Conditions

Interventions

DRUG

Rosuvastatin 10mg

Daily dose of one medication over 8 week period then switch to another medication over an 8 week period (type of medication during each intervention period is blinded and then randomized).

Sponsors & Collaborators

  • Vlaams Instituut Biotechnologie (VIB)

    collaborator UNKNOWN

  • Universitaire Ziekenhuizen KU Leuven

    lead OTHER

Principal Investigators

  • Severine Vermeire, MD & PhD · KU/UZ Leuven

  • Jeroen Raes, PhD · KU Leuven/VIB

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-22
Primary Completion
2025-10-11
Completion
2025-10-11

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04883840 on ClinicalTrials.gov